Showing results (101-110 of 584) with videos related to

Sort By:
Pageof 59
Bulletin Du Cancer|May 15, 2026
Radon and lung cancerEdouard Auclin, Maxime Janin, Laura Mezquita, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 13, 2013
ERCC1 and RRM1: ready for prime time?Benjamin Besse, Ken A Olaussen, Jean-Charles Soria
Immunotherapy|July 31, 2019
Non-small-cell lung cancer: what are the benefits and challenges of treating it with immune checkpoint inhibitors?Elie Rassy, Laura Mezquita, Jordi Remon, et al.
Lung Cancer (Amsterdam, Netherlands)|August 26, 2017
Peritoneal recurrence of thymoma treated by surgery and hyperthermic intraperitoneal chemotherapyCamille Mazza, Jordi Remon, Charles Honoré, et al.
European Journal of Cancer (Oxford, England : 1990)|April 10, 2019
Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?Arnaud Bayle, Benjamin Besse, Maxime Annereau, et al.
La Revue Du Praticien|March 16, 2010
[Screening and early diagnosis of other cancers (non-small cell lung carcinoma, urologic cancers, liver cancer and melanoma)]Michel Ducreux, Christine Mateus, David Planchard, et al.
JAMA Oncology|April 9, 2026
Outcomes and Treatments of Patients With Non-Small Cell Lung Cancer Who Received PembrolizumabAdrien Rousseau, Stéphanie Foulon, David Planchard, et al.
NPJ Precision Oncology|May 13, 2026
The novel ALK K1150dup mutation mediates resistance to frontline lorlatinib and retains sensitivity to gilteritinibMai Nagasaka, Francesco Facchinetti, Ludovic Bigot, et al.
European Journal of Cancer (Oxford, England : 1990)|October 10, 2017
A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancerJean-Charles Soria, Alex A Adjei, Rastilav Bahleda, et al.
British Journal of Cancer|November 26, 2019
Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancerWungki Park, Laura Mezquita, Naoyuki Okabe, et al.
Pageof 59